#United States #Greenwich #IMAgent #Vesselon #TriForm

Vesselon’s Groundbreaking Patent in Antibody Delivery

In a significant advancement for cancer treatment, Vesselon Inc. has recently been granted U.S. Patent Number 12,714,676. This patent covers a pioneering approach to enhancing the delivery of antibody-based therapeutics directly to tumors while minimizing exposure to healthy tissues, thus maintaining patients' overall health.

The Technology Behind the Patent

The patented technology revolves around a unique composition that combines microspheres, liposomes, and therapeutic antibodies. This innovative platform allows for the on-site co-formulation of biologics, specifically monoclonal antibodies, into microbubble/liposome complexes. An ultrasound activation mechanism facilitates this process, which has been shown to deliver approximately six times more medication directly to tumors while simultaneously reducing systemic exposure, an urgent need given the toxicity associated with conventional therapies.

Addressing the Shortcomings of Existing Treatments

Historically, many patients undergoing treatments with checkpoint inhibitors and other antibody drug conjugates often experience limited benefits, necessitating dose reductions or treatment cessation altogether. A recent study highlights that among 29 solid tumor types, 27 of them exhibited objective response rates below 25% for checkpoint inhibitor monotherapy. Consequently, this has raised questions regarding the overall effectiveness of these costly treatments, which can reach hundreds of thousands of dollars.

Clinical Validation of the Technology

A recent publication has validated the efficacy of Vesselon's co-formulation strategy, showcasing that its FDA-approved microsphere and liposome platform can significantly enhance the intratumoral delivery of the mouse version of Keytruda®. This delivery enhancement not only improves therapeutic outcomes but also significantly reduces the risk of toxicity to other organs, ensuring a safer treatment experience for patients.

Insights from Experts

Dr. Pier Paolo Claudio, a notable figure in pharmacology and toxicology from the University of Mississippi Medical Center, remarked on the platform’s transformative potential:

“Our findings indicate that Vesselon's co-formulation improves the delivery of checkpoint inhibitors, leading to improved survival rates while mitigating adverse effects on systemic organs, making this a promising avenue for advancing antibody-based immunotherapy.”

A Vision for the Future

Clay Larsen, President, and CEO of Vesselon, emphasized the innovative nature of this platform and its potential impact on the pharmaceutical industry.

“Pharmaceutical companies invest billions into the biochemistry of drug development. Our company leverages biophysics to optimize the delivery of life-saving drugs. This groundbreaking platform could transform the therapeutic index of numerous antibody classes, extending the life and effectiveness of current drugs facing patent expiration.”

Emphasizing the uniqueness of their approach, Vesselon has branded its co-formulation method as TriForm™. The mixing technique is quick and occurs directly within vials, resulting in formulations that include an impressive number of lipid microspheres and liposomes loaded with active drugs. This not only enhances the delivery efficacy but also establishes a new chemical entity that can be patented, ultimately creating a fortified pipeline for innovative drugs.

About Vesselon

Vesselon Inc. is dedicated to developing patentable drugs through its FDA-approved, biophysically activatable lipid microsphere and liposome platform. The company’s commitment to redefining the way medicines interact with tissues represents a promising frontier in drug delivery and efficacy, holding the potential to change the therapeutic landscape significantly.

In conclusion, Vesselon's groundbreaking advances present a compelling case for the integration of innovative drug delivery mechanisms in the fight against cancer, marking a significant leap forward in pharmacotherapy.